Internal Medicine Alert – August 30, 2022
August 30, 2022
View Issues
-
COVID-19: Duration of Shedding of Transmissible Virus
Patients with COVID-19 were found, by culture, to shed replication-competent virus after an initial PCR test for median durations of four to five days.
-
COVID-19 Rebound
Symptomatic and virologic recrudescence after treatment of patients with COVID-19 with Paxlovid occurs in a tiny percentage of patients and generally is mild and self-limited.
-
Inflammatory Foods Could Accelerate Brain Aging
In the Framingham Offspring cohort of subjects, those with a higher index of inflammatory foods recorded smaller brain volume, less grey matter.
-
The Value of Stress Testing in Patients with Known Coronary Artery Disease
A comparison of adenosine stress single-photon emission CT, PET, and MRI in stable patients with known coronary artery disease (CAD) showed PET to be more sensitive for detecting invasive fractional flow reserve-identified ischemic lesions. However, the sensitivity was disappointing. Patients with known CAD and new symptoms should be referred directly to invasive coronary angiography.
-
Rivaroxaban Monotherapy for Atrial Fibrillation in Coronary Artery Disease Patients
For patients with atrial fibrillation and stable coronary artery disease, rivaroxaban monotherapy was superior to dual therapy for preventing thrombotic and bleeding events and was associated with a lower mortality rate.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.